[go: up one dir, main page]

MX2021007268A - Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. - Google Patents

Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.

Info

Publication number
MX2021007268A
MX2021007268A MX2021007268A MX2021007268A MX2021007268A MX 2021007268 A MX2021007268 A MX 2021007268A MX 2021007268 A MX2021007268 A MX 2021007268A MX 2021007268 A MX2021007268 A MX 2021007268A MX 2021007268 A MX2021007268 A MX 2021007268A
Authority
MX
Mexico
Prior art keywords
solid forms
hydroxypyridine
chlorophenyl
carbonyl
amino
Prior art date
Application number
MX2021007268A
Other languages
English (en)
Inventor
James Densmore Copp
Ann W Newman
Anne Luong
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of MX2021007268A publication Critical patent/MX2021007268A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en la presente formas sólidas que comprenden ácido {[5-(3-clorofenil)-3-hidroxipiridin-2- carbonil]amino}acétic o, composiciones que comprenden las formas sólidas, métodos para elaborar las formas sólidas y métodos de su uso para el tratamiento de diversas enfermedades y/o trastornos.
MX2021007268A 2013-11-15 2016-05-13 Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. MX2021007268A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904803P 2013-11-15 2013-11-15

Publications (1)

Publication Number Publication Date
MX2021007268A true MX2021007268A (es) 2021-07-15

Family

ID=53058045

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021001169A MX2021001169A (es) 2013-11-15 2014-11-14 Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
MX2016006271A MX2016006271A (es) 2013-11-15 2014-11-14 Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MX2021007268A MX2021007268A (es) 2013-11-15 2016-05-13 Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2021001169A MX2021001169A (es) 2013-11-15 2014-11-14 Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
MX2016006271A MX2016006271A (es) 2013-11-15 2014-11-14 Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.

Country Status (24)

Country Link
US (7) US9701636B2 (es)
EP (2) EP3068394A4 (es)
JP (5) JP2016537365A (es)
KR (2) KR102495018B1 (es)
CN (2) CN105916502A (es)
AR (2) AR099354A1 (es)
AU (4) AU2014348523B2 (es)
BR (1) BR112016011065B1 (es)
CA (1) CA2930128A1 (es)
CL (1) CL2016001150A1 (es)
CR (2) CR20200220A (es)
DO (1) DOP2016000109A (es)
IL (2) IL245634A0 (es)
MA (1) MA39033A1 (es)
MX (3) MX2021001169A (es)
MY (1) MY180626A (es)
PE (1) PE20160945A1 (es)
PH (2) PH12021551124A1 (es)
RU (2) RU2021125455A (es)
SA (1) SA516371129B1 (es)
SG (2) SG10202012791TA (es)
TW (5) TWI846166B (es)
WO (1) WO2015073779A1 (es)
ZA (2) ZA201603189B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4095127A1 (en) 2006-06-26 2022-11-30 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
NO2686520T3 (es) 2011-06-06 2018-03-17
CN105451739A (zh) 2013-06-13 2016-03-30 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
CN105916502A (zh) * 2013-11-15 2016-08-31 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的固体形式，其组合物和用途
KR20160108554A (ko) * 2014-01-23 2016-09-19 아케비아 테라퓨틱스 인코포레이티드 안질환 치료용 조성물 및 치료방법
BR112017015852A2 (pt) * 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
EP3995138A1 (en) 2015-04-01 2022-05-11 Akebia Therapeutics Inc. Compositions and methods for treating anemia
CN105837502A (zh) * 2016-04-05 2016-08-10 湖南欧亚生物有限公司 一种Vadadustat的合成方法
CA3046377C (en) * 2016-12-13 2021-03-30 Crystal Pharmaceutical (Suzhou) Co., Ltd. Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid and processes for preparation thereof
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
WO2019217550A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
EP3887356B1 (en) 2018-11-28 2023-08-02 Sandoz AG Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
IT202000014116A1 (it) 2020-06-12 2021-12-12 Olon Spa Nuovo composto cristallino di vadadustat
CN111825606A (zh) * 2020-06-17 2020-10-27 上海希迈医药科技有限公司 一种伐度司他晶型及其制备方法
PH12022553525A1 (en) * 2020-06-19 2024-06-24 Akebia Therapeutics Inc Modulation of drug-drug interactions of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
WO2022048613A1 (zh) * 2020-09-04 2022-03-10 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
IL303961A (en) 2021-01-08 2023-08-01 Akebia Therapeutics Inc Therapeutic methods using VADADUSTAT
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
AU2022229275A1 (en) * 2021-03-01 2023-10-12 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
BR8807740A (pt) 1988-07-25 1990-10-16 V Kurgansky Nauchny Ts Vosstan Aparelho de tracao para reconstrucao plastica da mao
TW219933B (es) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK0650960T3 (da) 1993-11-02 1997-09-01 Hoechst Ag Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
KR20000065090A (ko) 1996-04-30 2000-11-06 훽스트 악티엔게젤샤프트 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
KR20010042125A (ko) 1998-03-23 2001-05-25 오흘러 로스 제이. 피페리디디닐 및 ｎ-아미디노피페리디닐 유도체
AU5698899A (en) 1998-08-27 2000-03-21 Teva Pharmaceutical Industries Ltd. Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
IL143311A0 (en) 1998-11-27 2002-04-21 Teva Pharma Sertraline hydrochloride polymorphs
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
EP1207880A4 (en) 1999-08-11 2004-09-01 Teva Pharma TORSEMIDE POLYMORPHS
SK286789B6 (sk) 1999-11-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Kryštalická forma atorvastatínu vápenatého alebo jeho hydrátu, spôsob jej prípravy a farmaceutická kompozícia s jej obsahom
US7001919B2 (en) 1999-12-14 2006-02-21 Teva Gyogyszergyar Reszvenytarsasag Forms of pravastatin sodium
IL150227A0 (en) 1999-12-16 2002-12-01 Teva Pharma Processes for preparing clarithromycin polymorphs and novel polymorph iv
JP2003517011A (ja) 1999-12-16 2003-05-20 テバ ファーマシューティカル インダストリーズ リミティド レフルノミドの新規な製法及び新しい結晶形態
ES2281374T3 (es) 1999-12-21 2007-10-01 Teva Pharmaceutical Industries Ltd. Nuevos polimorfos de hidrocloruro de sertralina, procedimientos para su preparacion, composiciones que los contienen y metodos para su utilizacion.
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
ATE288758T1 (de) 2000-01-11 2005-02-15 Teva Pharma Verfahren zur herstellung von polymorphen des clarithromycins
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
MXPA03000747A (es) 2000-07-27 2003-06-04 Teva Pharma Modafinilo cristalino y puro y proceso para prepararlo.
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
AU2002241764A1 (en) 2000-10-19 2002-06-18 Teva Pharmaceutical Industries Ltd. Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
ES2204358T1 (es) 2000-10-30 2004-05-01 Teva Pharmaceutical Industries Ltd. Nuevas formas de cristal y de disolvente de hidrocloruro de ondasetron y procedimientos para su preparacion.
CA2426632C (en) 2000-11-03 2008-08-05 Teva Pharmaceutical Industries, Ltd. Atorvastatin hemi-calcium form vii
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002250057A1 (en) 2001-02-12 2002-08-28 Teva Pharmaceutical Industries Ltd. New crystal forms of oxcarbazepine and processes for their preparation
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
SK13822003A3 (sk) 2001-04-09 2004-09-08 Teva Pharmaceutical Industries Ltd. Polymorfné formy chloridu fexofenadínu
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
WO2003011228A2 (en) 2001-08-01 2003-02-13 Biogal Gyogyszergyar Rt Purification and crystalline forms of zaleplon
EP1436295A4 (en) 2001-09-07 2007-07-11 Teva Pharma CRISTALLINE FORMS OF VALACYCLOVIR HYDROCHLORIDE
AU2002341990A1 (en) 2001-10-03 2003-04-14 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and forms thereof
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003039482A2 (en) 2001-11-08 2003-05-15 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine base
CA2465597A1 (en) 2001-11-14 2003-06-12 Ben Zion Dolitzky Amorphous and crystalline forms of losartan potassium and process for their preparation
EP1470116A4 (en) 2001-12-04 2005-04-06 Biogal Gyogyszergyar PREPARATION OF THE ORLISTAT AND CRYSTALLINE FORMS OF THE ORLISTAT
CN100522946C (zh) 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
WO2003051362A2 (en) 2001-12-18 2003-06-26 Teva Pharmaceutical Industries Ltd. Polymorphs of clopidogrel hydrogensulfate
KR20040075857A (ko) 2001-12-28 2004-08-30 비오갈 기오기스제르갸르 알티. 결정질 및 비결정질 무피로신 칼슘의 제조 방법
CA2472377A1 (en) 2002-01-15 2003-07-24 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
EP1480950A4 (en) 2002-02-15 2005-05-18 Teva Pharma NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX
AU2003235435A1 (en) 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
CA2480352A1 (en) 2002-03-27 2003-10-09 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
CN101024654A (zh) 2002-04-11 2007-08-29 特瓦制药工业有限公司 利塞膦酸钠的新多晶型物和假多晶型物
WO2003093217A1 (en) 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
PL373192A1 (en) 2002-04-30 2005-08-22 Teva Gyogyszergyar Reszvenytarsasag Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
PL373788A1 (en) 2002-05-10 2005-09-19 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
US20040044038A1 (en) 2002-06-10 2004-03-04 Barnaba Krochmal Polymorphic form XVI of fexofenadine hydrochloride
CN1674902A (zh) 2002-06-14 2005-09-28 特瓦制药工业有限公司 新晶型的加替沙星
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
WO2004009532A1 (en) 2002-07-18 2004-01-29 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20040022764A1 (en) * 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
AU2003258109A1 (en) 2002-08-06 2004-02-23 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
EP1532151A2 (en) 2002-08-26 2005-05-25 Teva Pharmaceutical Industries Limited Crystalline solid famciclovir forms i, ii, iii and preparation thereof
US20050043329A1 (en) 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
AU2003297594A1 (en) 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
EP1485097A1 (en) 2002-12-12 2004-12-15 Teva Pharmaceutical Industries Limited Crystalline forms of gatifloxacin and processes for preparation
WO2004058773A1 (en) 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
WO2004108700A1 (en) 2003-03-12 2004-12-16 Teva Gyogyszergyar Reszvenytarsasag Processes for preparation of polymorphic forms of desloratadine
EP1601667A2 (en) 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline and amorphous solids of pantoprazole and processes for their preparation
US20040242661A1 (en) 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
US7452991B2 (en) 2003-05-15 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Aztreonam β polymorph with very low residual solvent content
EP1638972A2 (en) 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
US20050043324A1 (en) 2003-06-03 2005-02-24 Tamas Koltai Polymorphic forms of ziprasidone HCI and processes for their preparation
BRPI0411055B1 (pt) 2003-06-06 2018-08-21 Fibrogen, Inc Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
KR20060024428A (ko) 2003-06-18 2006-03-16 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 결정 형태, 이것의 제조 방법, 상기결정 형태를 포함하는 조성물 및 상기 결정 형태를이용하는 방법
US20050054616A1 (en) 2003-07-03 2005-03-10 Judith Aronhime Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
TW200529850A (en) 2003-12-16 2005-09-16 Teva Pharma Methods of preparing aripiprazole crystalline forms
WO2005058819A2 (en) 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CN1934108A (zh) 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
JP2007518826A (ja) 2004-01-30 2007-07-12 テバ ファーマシューティカル インダストリーズ リミティド モンテルカスト遊離酸多形体
US20050187244A1 (en) 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
EP1628959A2 (en) 2004-04-26 2006-03-01 Teva Pharmaceutical Industries Ltd Crystalline forms of fexofenadine hydrochloride and processes for their preparation
US20060004102A1 (en) 2004-05-07 2006-01-05 Shlomit Wizel Polymorphic forms of nateglinide
US7473780B2 (en) 2004-05-18 2009-01-06 Teva Pharmeceutical Industries Ltd. Drying process for preparing crystalline solid famciclovir
US7488758B2 (en) 2004-05-20 2009-02-10 Teva Pharmaceutical Fine Chemicals, S.R.L. Levalbuterol hydrochloride polymorph B
MX2007000087A (es) 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
EP2174935A1 (en) 2004-06-29 2010-04-14 Teva Pharmaceutical Industries Ltd Linezolid Compositions
JP2008504369A (ja) 2004-07-01 2008-02-14 テバ ファーマシューティカル インダストリーズ リミティド １，２４（ｓ）−ジヒドロキシビタミンｄ２の結晶形態
JP2008506783A (ja) 2004-07-20 2008-03-06 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸ナトリウムの結晶形の調製方法
ES2262459T1 (es) 2004-07-22 2006-12-01 Teva Pharmaceutical Industries Ltd Nuevas formas cristalinas de atorvastatina semicalcica y procedimientos para su preparacion.
CN1976894A (zh) 2004-07-22 2007-06-06 特瓦药物精化学品股份有限公司 阿托莫西汀盐酸盐的多形体
DE602005025977D1 (de) 2004-08-23 2011-03-03 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
US20060154957A1 (en) 2004-09-21 2006-07-13 Nina Finkelstein Crystalline clopidogrel hydrobromide and processes for preparation thereof
JP2008514641A (ja) 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
EP1799216A2 (en) 2004-11-02 2007-06-27 Teva Pharmaceutical Industries Ltd Tadalafil crystal forms and processes for preparing them
WO2006050509A2 (en) 2004-11-03 2006-05-11 Teva Pharmaceutical Industries Ltd. Amorphous and polymorphic forms of telmisartan sodium
US20060211751A1 (en) 2004-11-19 2006-09-21 Reuven Izsak Zolmitriptan crystal forms
EP1817315A1 (en) 2004-12-01 2007-08-15 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Processes for producing crystalline macrolides
JP2007526251A (ja) 2004-12-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド エゼチミベ多形体
US7462743B2 (en) 2005-01-11 2008-12-09 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of memantine hydrochloride
WO2006081515A2 (en) 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride polymorphs
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
CN101128420A (zh) 2005-02-24 2008-02-20 泰华制药工业有限公司 拉多斯迪戈酒石酸盐结晶体、其制备方法及其药物组合物
MX2007010141A (es) 2005-02-24 2007-09-27 Teva Pharma Procesos para la preparacion de intermedios de linezolid.
US7399871B2 (en) 2005-03-08 2008-07-15 Teva Pharmaceutical Industries Ltd. Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof
WO2006098834A2 (en) 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
MX2007012396A (es) 2005-04-06 2007-11-20 Teva Pharma Formas cristalinas de pregabalina.
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
EP1805135A2 (en) 2005-05-23 2007-07-11 Teva Pharmaceutical Industries Ltd. Purification of cinacalcet
JP4750184B2 (ja) 2005-05-23 2011-08-17 キャドバリー アダムス ユーエスエー エルエルシー 味覚増強組成物並びに味覚増強組成物を含有する、食用菓子製品及びチューインガム製品
WO2006133391A2 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
WO2007008317A2 (en) 2005-06-09 2007-01-18 Teva Pharmaceutical Industries Ltd. Process for preparation of sertraline hydrochloride form i
US20070043099A1 (en) 2005-06-09 2007-02-22 Igor Lifshitz Crystalline forms of carvedilol and processes for their preparation
US8530404B2 (en) 2005-06-15 2013-09-10 Fibrogen, Inc. Compounds and methods for treatment of cancer
US20070112057A1 (en) 2005-06-22 2007-05-17 Santiago Ini Polymorphic forms of tegaserod maleate
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007038676A2 (en) 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
RS53666B1 (en) 2005-10-19 2015-04-30 Teva Pharmaceutical Industries Ltd CRYSTALS OF SODIUM LAKVINIMOD AND THE PROCESS FOR OBTAINING THEM
KR100912214B1 (ko) 2005-10-31 2009-08-14 테바 파마슈티컬 인더스트리즈 리미티드 세프디니르 세슘 염의 결정형
WO2007053724A2 (en) 2005-10-31 2007-05-10 Teva Pharmaceutical Industries Ltd. Crystalline forms of cefdinir potassium salt
US20070167382A1 (en) 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
CA2625299A1 (en) 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
KR20080007561A (ko) 2005-12-13 2008-01-22 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
EP1968588A2 (en) 2006-01-05 2008-09-17 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Crystalline forms of dolasetron base and processes for preparation thereof
BRPI0706377A2 (pt) 2006-01-09 2011-03-22 Btg Int Ltd moduladores de fator -1 induzìvel por hipoxia e usos relacionados
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
US20070208072A1 (en) 2006-01-18 2007-09-06 Gustavo Frenkel Maleate salt of tegaserod and crystalline forms thereof
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
KR20070119037A (ko) 2006-02-21 2007-12-18 테바 파마슈티컬 인더스트리즈 리미티드 아르모다피닐의 신규한 결정질 형태 및 이것의 제조 방법
EP1904444A2 (en) 2006-02-27 2008-04-02 Teva Pharmaceutical Industries Ltd Fluvastatin sodium novel forms and preparation therof
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
US20080027223A1 (en) 2006-03-23 2008-01-31 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
EP4095127A1 (en) 2006-06-26 2022-11-30 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
CA2683738C (en) 2007-04-18 2012-03-20 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
CN101663037A (zh) 2007-04-18 2010-03-03 默克公司 新的1,8-二氮杂萘化合物
ES2389063T3 (es) 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
JP5349462B2 (ja) 2007-05-16 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション スピロインダロン
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
WO2009037570A2 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009061910A1 (en) 2007-11-08 2009-05-14 Genetech, Inc. Anti-factor b antibodies and their uses
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
CN101983384A (zh) 2007-11-30 2011-03-02 葛兰素史密斯克莱有限责任公司 脯氨酰羟化酶抑制剂
US20100305154A1 (en) 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2240178A4 (en) 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
EP2717870B1 (en) 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
NO2686520T3 (es) 2011-06-06 2018-03-17
JP6099644B2 (ja) * 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
US8772895B2 (en) 2011-11-28 2014-07-08 Taiwan Semiconductor Manufacturing Company, Ltd. Dark current reduction for back side illuminated image sensor
EP2637274B1 (en) 2012-03-05 2022-05-04 Vetco Gray Scandinavia AS Power cable termination arrangement
CN105451739A (zh) 2013-06-13 2016-03-30 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
CN105916502A (zh) 2013-11-15 2016-08-31 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的固体形式，其组合物和用途
KR20160108554A (ko) 2014-01-23 2016-09-19 아케비아 테라퓨틱스 인코포레이티드 안질환 치료용 조성물 및 치료방법
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
WO2016153996A1 (en) 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
EP3995138A1 (en) 2015-04-01 2022-05-11 Akebia Therapeutics Inc. Compositions and methods for treating anemia
CA3046377C (en) 2016-12-13 2021-03-30 Crystal Pharmaceutical (Suzhou) Co., Ltd. Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid and processes for preparation thereof
WO2019217550A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
MX2022005104A (es) 2019-10-31 2022-07-21 Akebia Therapeutics Inc Métodos terapéuticos mediante el uso de vadadustat.
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
KR102381295B1 (ko) 2022-03-31
NZ719970A (en) 2022-03-25
CR20160222U (es) 2016-08-26
TWI788702B (zh) 2023-01-01
CL2016001150A1 (es) 2016-12-09
TW201946625A (zh) 2019-12-16
ZA201905255B (en) 2020-11-25
RU2016123382A (ru) 2017-12-20
AU2020294308B2 (en) 2022-08-11
AU2019202144B2 (en) 2020-10-08
US9987262B2 (en) 2018-06-05
NZ759132A (en) 2022-03-25
AU2020294308A1 (en) 2021-02-18
MX2016006271A (es) 2017-05-04
IL281648A (en) 2021-05-31
KR20220042498A (ko) 2022-04-05
JP2022176961A (ja) 2022-11-30
CN105916502A (zh) 2016-08-31
US20180280365A1 (en) 2018-10-04
SG10201803862UA (en) 2018-06-28
AU2022259767A1 (en) 2022-12-01
ZA201603189B (en) 2019-11-27
US20200345711A1 (en) 2020-11-05
TW202335670A (zh) 2023-09-16
US11065237B2 (en) 2021-07-20
TW202435877A (zh) 2024-09-16
PE20160945A1 (es) 2016-09-26
PH12021551124A1 (en) 2024-04-29
US11690836B2 (en) 2023-07-04
PH12016500866A1 (en) 2016-06-20
EP3578546A1 (en) 2019-12-11
US10149842B2 (en) 2018-12-11
TWI846166B (zh) 2024-06-21
BR112016011065B1 (pt) 2022-10-25
TW202126300A (zh) 2021-07-16
RU2021125455A (ru) 2021-10-05
AU2019202144A1 (en) 2019-04-18
US10596158B2 (en) 2020-03-24
CN114890943A (zh) 2022-08-12
AR099354A1 (es) 2016-07-20
US20190290624A1 (en) 2019-09-26
MX2021001169A (es) 2023-02-10
MA39033A1 (fr) 2017-11-30
SA516371129B1 (ar) 2019-07-28
US20220040159A1 (en) 2022-02-10
TWI665190B (zh) 2019-07-11
CA2930128A1 (en) 2015-05-21
KR102495018B1 (ko) 2023-02-06
BR112016011065A8 (pt) 2020-04-22
AU2014348523B2 (en) 2019-01-03
TW201605801A (zh) 2016-02-16
US20240122910A1 (en) 2024-04-18
JP2025011163A (ja) 2025-01-23
BR112016011065A2 (pt) 2017-08-08
AU2014348523A1 (en) 2016-06-09
JP2016537365A (ja) 2016-12-01
EP3068394A4 (en) 2017-04-26
IL245634A0 (en) 2016-06-30
WO2015073779A1 (en) 2015-05-21
CR20200220A (es) 2020-11-18
AU2022259767B2 (en) 2024-08-15
US9701636B2 (en) 2017-07-11
AR128483A2 (es) 2024-05-15
SG10202012791TA (en) 2021-01-28
JP2020183408A (ja) 2020-11-12
KR20160083118A (ko) 2016-07-11
DOP2016000109A (es) 2016-08-31
MY180626A (en) 2020-12-03
US20150141467A1 (en) 2015-05-21
EP3068394A1 (en) 2016-09-21
US20170258773A1 (en) 2017-09-14
JP2019167353A (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
AU2018236800B2 (en) DNA-PK inhibitors
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
WO2015073587A3 (en) Synthetic membrane-receiver complexes
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
WO2016037157A3 (en) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
WO2015001504A3 (en) Antibody formulations and methods
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
PH12018501072A1 (en) Modified release orally administered amino acid formulations
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
PH12017500089B1 (en) Aldosterone synthase inhibitors
PH12012501389A1 (en) Hedgehog inhibitors
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
WO2012123561A3 (de) Agens zur prophylaxe und behandlung altersassoziierter krankheiten und störungen sowie zur verlängerung der lebensdauer
PH12020500472A1 (en) Autotaxin inhibitor compounds